“We Regulators Need To Get Our Heads Round Big Data”: EU Task Force Chair
Executive Summary
The EU big data task force seems to be on track to deliver in 2018 an EU-wide strategy on how big data can be used to support the development and evaluation of medicines. Some aspects of big data, such as social media and mobile health, have proved to be more challenging than others, says task force co-chair Thomas Senderovitz.
You may also be interested in...
EMA Takes A Dive Into Patient-Level Data
The European Medicines Agency will begin a pilot in 2021 to examine the practical aspects of undertaking patient-level data assessments during medicines evaluation and identify scenarios when such assessments might be useful.
Interview: EU Big Data Task Force Is ‘Not Just Another Discussion Forum’, Says Chair Thomas Senderovitz
A month after EU regulators created a task force to work out how to use big data to support drug evaluation, Thomas Senderovitz, the head of the Danish Medicines Agency who chairs the new group, tells the Pink Sheet’s Vibha Sharma what to expect from the initiative.
Denmark Leads New EU Task Force Exploring Use Of Big Data In Medicines Assessment
EU drug regulators have created a new task force to establish a roadmap and recommendations on how to use big data in the assessment of medicines.